Quidel (QDEL) and BioHelix to Jointly Develop and Commercialize In Vitro Molecular and Diagnostic Tests

October 6, 2009 7:56 AM EDT

Quidel Corporation (NASDAQ: QDEL) announced a joint development and commercialization agreement will BioHelix Corporation that will focus on in vitro molecular and diagnostic tests. These tests will utilize BioHelix's isothermal amplification technology to assay rapid detection of infectious pathogens in a non-instrumented, handheld format .

Under the partnership, Quidel will fund and jointly develop with BioHelix assays for rapid detection of infectious pathogens in a non-instrumented, handheld format utilizing BioHelix's isothermal amplification technology. BioHelix undertakes primary responsibility for assay development while Quidel has primary responsibility for manufacturing, marketing and selling the new products developed under the agreement and exclusive, worldwide commercialization rights for the new products.

"We are extremely pleased with this strategic partnership as both companies look to leverage their respective strengths in bringing novel diagnostic solutions to the clinical diagnostic market," commented Douglas Bryant, president and chief executive officer of Quidel Corporation. Huimin Kong, Ph.D., president and chief executive officer of BioHelix Corporation, added, "We are excited to work with Quidel in the further development and commercialization of simple, cost-effective molecular diagnostic tests, which is a major focus for our company."

Related Categories

Corporate News

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?